Retatrutide GLP-1 Isn't Approved. MILLIONS Are Already Using It RIGHT NOW.
Community Score: 50% | 134.9K views | 3d
0 community ratings: null thumbs up, null thumbs down
Retatrutide could become the most powerful weight-loss drug yet, and it may push obesity treatment into completely new territory. Unlike Ozempic and Wegovy, which primarily target GLP-1, Retatrutide activates three hormone pathways at once: GLP-1, GIP, and glucagon. That combination is what makes it different. GLP-1 suppresses appetite. GIP helps regulate how the body processes incoming energy. And glucagon may push the body toward releasing stored fuel rather than simply consuming less of it. The results have attracted enormous attention. Clinical trials have reported average weight loss approaching 30% of total body weight at the highest doses-levels that begin to resemble outcomes traditionally associated with bariatric surgery. But Retatrutide is still investigational. Researchers are continuing to study its long-term safety, including effects on heart rate, muscle loss, and neurological symptoms such as dysesthesia. Meanwhile, unapproved versions are already being sold online, de
More from The Infographics Show
- Weirdest Mysteries Scientists Can't Explain — Score: 50%
- AI is Now CHOOSING Targets. The Kill Chain is BROKEN — Score: 50%
- How Did People Sleep in Medieval Castles Without Freezing to Death — Score: 50%
- Sora was Empty: 99% of Users QUIT — Score: 50%
- Something in Alaska is Making People Disappear — Score: 50%
- AI Played A War Game. It NUKED Everyone — Score: 50%